Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Legal Officer | September 13, 2011 | September 14, 2011 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date September 13, 2011 · Filed September 14, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,999 |
Ending reported balance
After 2011-09-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2011-09-13 · Exercise / conversion · Acquired 22,000 · Balance 134,999 Row 2 · 2011-09-13 · Sale · Disposed 22,000 · Balance 112,999 F1: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $18.75 · Expires 2011-09-23 | Direct | 0 |
Reported balance
After 2011-09-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2011-09-13 · Exercise / conversion · Disposed 22,000 · Balance 0 F3: Fully vested. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 5,021 |
Reported balance
Holding disclosure · report date 2011-09-13 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,021 |
| Common StockSEC Table I · non-derivative | IndirectTrustee of Trusts | 174,167 |
Reported balance
Holding disclosure · report date 2011-09-13 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 174,167 F2: Kenneth S. Boger is the trustee for trusts established for the benefit of the three adult children of Joshua S. Boger (a director of the issuer). |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1.
F2: Kenneth S. Boger is the trustee for trusts established for the benefit of the three adult children of Joshua S. Boger (a director of the issuer).
F3: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2011 Filed Sep 14, 2011 16:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 22,000 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-11-047799 · doc4.xml · derivative · entry 5 BOGER KENNETH S · CIK 0001046336 · SVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,000 shares Expires 2011-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| September 13, 2011 Filed Sep 14, 2011 16:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 22,000 | $50.00 | $1,100,000.00 |
DisclosureSEC source: 0001209191-11-047799 · doc4.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,999 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. Read SEC document |
| September 13, 2011 Filed Sep 14, 2011 16:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 22,000 | $18.75 | $412,500.00 |
DisclosureSEC source: 0001209191-11-047799 · doc4.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2011 Filed Aug 1, 2011 18:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,334 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-11-041692 · doc4.xml · derivative · entry 5 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 7,334 shares Expires 2011-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| July 29, 2011 Filed Aug 1, 2011 18:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,334 | $50.00 | $366,700.00 |
DisclosureSEC source: 0001209191-11-041692 · doc4.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,999 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 29, 2011 Filed Aug 1, 2011 18:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,334 | $18.75 | $137,512.50 |
DisclosureSEC source: 0001209191-11-041692 · doc4.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2011 Filed Jul 21, 2011 19:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,333 | $50.04 | $366,943.32 |
DisclosureSEC source: 0001209191-11-040456 · doc4.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,999 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $50.04 (range $50.00 to $50.47). F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 20, 2011 Filed Jul 21, 2011 19:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,333 | $18.75 | $137,493.75 |
DisclosureSEC source: 0001209191-11-040456 · doc4.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2011 Filed Jul 14, 2011 19:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-11-039505 · doc4.xml · derivative · entry 6 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2021-07-12 F6 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/13/2011. Read SEC document |
| July 13, 2011 Filed Jul 14, 2011 19:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,334 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-11-039505 · doc4.xml · derivative · entry 5 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,667 Underlying: Common Stock · 7,334 shares Expires 2011-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| July 13, 2011 Filed Jul 14, 2011 19:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,334 | $51.92 | $380,781.28 |
DisclosureSEC source: 0001209191-11-039505 · doc4.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,999 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $51.92 (range $51.51 to $52.25). F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 13, 2011 Filed Jul 14, 2011 19:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,334 | $18.75 | $137,512.50 |
DisclosureSEC source: 0001209191-11-039505 · doc4.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2011 Filed Jul 21, 2011 19:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,333 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-11-040456 · doc4.xml · derivative · entry 5 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,334 Underlying: Common Stock · 7,333 shares Expires 2011-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| July 06, 2011 Filed Jul 7, 2011 18:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,333 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-11-038667 · doc4.xml · derivative · entry 6 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,001 Underlying: Common Stock · 7,333 shares Expires 2011-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| July 06, 2011 Filed Jul 7, 2011 18:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 120 | $51.73 | $6,207.60 |
DisclosureSEC source: 0001209191-11-038667 · doc4.xml · nonDerivative · entry 3 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,999 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $51.73 (range $51.18 to $51.84). Read SEC document |
| July 06, 2011 Filed Jul 7, 2011 18:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,213 | $50.29 | $362,741.77 |
DisclosureSEC source: 0001209191-11-038667 · doc4.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,119 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $50.29 (range $50.00 to $50.73). F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2011 Filed Jul 7, 2011 18:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,333 | $18.75 | $137,493.75 |
DisclosureSEC source: 0001209191-11-038667 · doc4.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2011 Filed Jun 30, 2011 18:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,334 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-11-036876 · doc4.xml · derivative · entry 6 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,334 Underlying: Common Stock · 7,334 shares Expires 2011-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| June 29, 2011 Filed Jun 30, 2011 18:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,458 | $51.63 | $281,796.54 |
DisclosureSEC source: 0001209191-11-036876 · doc4.xml · nonDerivative · entry 3 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,999 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $51.63 (range $51.02 to $51.88). Read SEC document |
| June 29, 2011 Filed Jun 30, 2011 18:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,876 | $50.64 | $95,000.64 |
DisclosureSEC source: 0001209191-11-036876 · doc4.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,457 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $50.64 (range $50.37 to $50.94). F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 29, 2011 Filed Jun 30, 2011 18:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,334 | $18.75 | $137,512.50 |
DisclosureSEC source: 0001209191-11-036876 · doc4.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2011 Filed Jun 29, 2011 19:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 14,667 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-11-036721 · doc4.xml · derivative · entry 5 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,668 Underlying: Common Stock · 14,667 shares Expires 2011-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| June 28, 2011 Filed Jun 29, 2011 19:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 14,667 | $50.00 | $733,350.00 |
DisclosureSEC source: 0001209191-11-036721 · doc4.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,999 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. Read SEC document |
| June 28, 2011 Filed Jun 29, 2011 19:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 14,667 | $18.75 | $275,006.25 |
DisclosureSEC source: 0001209191-11-036721 · doc4.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2011 Filed Jun 10, 2011 12:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,333 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-11-033964 · doc4.xml · derivative · entry 5 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,335 Underlying: Common Stock · 7,333 shares Expires 2011-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| June 08, 2011 Filed Jun 10, 2011 12:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,333 | $53.38 | $391,435.54 |
DisclosureSEC source: 0001209191-11-033964 · doc4.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,999 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $53.38 (range $52.98 to $54.12). F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 08, 2011 Filed Jun 10, 2011 12:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,333 | $18.75 | $137,493.75 |
DisclosureSEC source: 0001209191-11-033964 · doc4.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2011 Filed Jun 2, 2011 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,334 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-11-032533 · doc4.xml · derivative · entry 6 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,668 Underlying: Common Stock · 7,334 shares Expires 2011-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2011 Filed Jun 2, 2011 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $54.14 | $59,554.00 |
DisclosureSEC source: 0001209191-11-032533 · doc4.xml · nonDerivative · entry 3 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,999 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $54.14 (range $54.00 to $54.50). Read SEC document |
| June 01, 2011 Filed Jun 2, 2011 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,234 | $53.59 | $334,080.06 |
DisclosureSEC source: 0001209191-11-032533 · doc4.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,099 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $53.59 (range $53.21 to $53.98). F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2011 Filed Jun 2, 2011 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,334 | $18.75 | $137,512.50 |
DisclosureSEC source: 0001209191-11-032533 · doc4.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2011 Filed May 26, 2011 20:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,489 | $56.23 | $139,956.47 |
DisclosureSEC source: 0001209191-11-031297 · doc4.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,999 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $56.23 (range $56.01 to $56.46). Read SEC document |
| May 25, 2011 Filed May 26, 2011 20:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,577 | $55.56 | $87,618.12 |
DisclosureSEC source: 0001209191-11-031297 · doc4.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,488 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $55.56 (range $55.14 to $55.95). F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 02, 2011 Filed May 3, 2011 19:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 5,000 | $0.00 Strike: $24.66 | $0.00 |
DisclosureSEC source: 0001209191-11-025599 · doc4.xml · derivative · entry 6 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2011-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| May 02, 2011 Filed May 3, 2011 19:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,386 | $56.01 | $77,629.86 |
DisclosureSEC source: 0001209191-11-025599 · doc4.xml · nonDerivative · entry 3 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,752 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $56.01 (range $55.90 to $56.48). Read SEC document |
| May 02, 2011 Filed May 3, 2011 19:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,614 | $55.57 | $200,829.98 |
DisclosureSEC source: 0001209191-11-025599 · doc4.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,138 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $55.57 (range $55.06 to $55.88). F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 02, 2011 Filed May 3, 2011 19:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $24.66 | $123,300.00 |
DisclosureSEC source: 0001209191-11-025599 · doc4.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2011 Filed Apr 4, 2011 18:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | OtherCommon Stock | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-020912 · doc4.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · Trustee of Trusts Disclosed balance after: 174,167 F1 · kind: Kenneth S. Boger is the trustee for trusts established for the benefit of the three adult children of Joshua S. Boger (a director of the issuer) that held 207,500 shares of common stock. On March 31, 2011, one of Joshua S. Boger's children withdrew 33,333 shares of Vertex common stock from a trust formed for his benefit. Kenneth S. Boger disclaims beneficial ownership of the 174,167 shares held in the trusts. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 45,750 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000009 · edgar.xml · derivative · entry 3 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-11-000009 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,752 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| July 14, 2010 Filed Jul 16, 2010 19:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0000875320-10-000040 · edgar.xml · derivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common STock · 30,500 shares Expires 2020-07-13 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/14/2010. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 76,250 | $0.00 Strike: $39.05 | $0.00 |
DisclosureSEC source: 0000875320-10-000008 · edgar.xml · derivative · entry 3 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,250 Underlying: Common Stock · 76,250 shares Expires 2020-02-03 F2 · shares: Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years. Read SEC document |
| February 04, 2010 Filed Feb 8, 2010 18:43 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-10-000008 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,023 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| October 22, 2009 Filed Oct 26, 2009 20:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 30,000 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0000875320-09-000089 · edgar.xml · derivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2019-10-21 F1 · derivative.exercise_date: Stock option under 2006 Stock and Option Plan, vesting on 10/22/2014, subject to 100% acceleration upon receiving marketing approval from the FDA for telaprevir. Read SEC document |
| August 03, 2009 Filed Aug 4, 2009 19:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 3,024 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0000875320-09-000073 · edgar.xml · derivative · entry 6 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,024 shares Expires 2015-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| August 03, 2009 Filed Aug 4, 2009 19:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 17,820 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0000875320-09-000073 · edgar.xml · derivative · entry 5 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,820 shares Expires 2011-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| August 03, 2009 Filed Aug 4, 2009 19:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 20,844 | $36.02 | $750,800.88 |
DisclosureSEC source: 0000875320-09-000073 · edgar.xml · nonDerivative · entry 3 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,857 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan established under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $36.02 (range $36.00 to $36.26). F4 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2009 Filed Aug 4, 2009 19:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,024 | $17.16 | $51,891.84 |
DisclosureSEC source: 0000875320-09-000073 · edgar.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2009 Filed Aug 4, 2009 19:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 17,820 | $18.75 | $334,125.00 |
DisclosureSEC source: 0000875320-09-000073 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2009 Filed Jul 29, 2009 18:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 1,547 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-09-000071 · edgar.xml · derivative · entry 8 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,547 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.